Boehringer plays catch-up in COPD with its latest FDA approval

July 31, 2014 6:57 PM

15 0

The FDA approved Boehringer Ingelheim's COPD treatment Striverdi Respimat, a once-a-day inhaler the German drugmaker hopes can contend in a crowded respiratory market.

The treatment, developed as olodaterol, is a long-acting beta2 agonist (LABA) that works to ease airway muscles and prevent symptoms of lung ailments like chronic bronchitis and emphysema. The FDA nod clears Boehringer to market its drug for COPD, the third-leading cause of death in the U.S., and, l...

Also read: BRIEF-Hexagon CEO says work continues with "business as usual" after news of chairman stepping down

Read more

To category page